Taysha Gene Therapies Inc. (TSHA)
Market Closed
16 Oct, 08:00 PM
NASDAQ (NGS) NASDAQ (NGS) Primary $
3. 62
-0.11
-2.9491%
$
1.44B Market Cap
- P/E Ratio
- Div Yield
2.75M Volume
-0.41 Eps
$ 3.73
Previous Close 
Want to track TSHA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Lags Revenue Estimates
Taysha Gene Therapies, Inc. (TSHA) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.38 per share a year ago.
Zacks | 2 years ago
Why Is Taysha Gene Therapies (TSHA) Stock Down 14% Today?
Taysha Gene Therapies (NASDAQ: TSHA ) stock is taking a beating on Wednesday after the gene therapy company announced a proposed public offering for its shares. Taysha Gene Therapies says that it intends to offer up to $75 million worth of TSHA stock in this offering.
Investorplace | 2 years ago
What's Going On With Taysha Gene Therapies Stock Tuesday?
Tuesday, Taysha Gene Therapies Inc TSHA released longer-term clinical data from the ongoing REVEAL Phase 1/2 adolescent and adult trial and initial clinical data from the REVEAL Phase 1/2 pediatric trial evaluating TSHA-102 in Rett syndrome.
Benzinga | 2 years ago
2026 © Marketlog. All Rights Reserved.
